for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dynavax Technologies Corporation

DVAX.O

Latest Trade

13.15USD

Change

0.42(+3.30%)

Volume

1,894,296

Today's Range

12.76

 - 

13.97

52 Week Range

4.93

 - 

21.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.73
Open
12.90
Volume
1,894,296
3M AVG Volume
47.59
Today's High
13.97
Today's Low
12.76
52 Week High
21.39
52 Week Low
4.93
Shares Out (MIL)
119.95
Market Cap (MIL)
1,526.99
Forward P/E
30.49
Dividend (Yield %)
--

Next Event

Q4 2021 Dynavax Technologies Corp Earnings Release

Latest Developments

More

Dynavax And U.S. Department Of Defense Announce Collaboration To Develop An Adjuvanted Plague Vaccine Using Dynavax's Cpg 1018 Adjuvant

Clover Biopharmaceuticals Says Favorable Safety Profile In Spectra Trial

Dynavax Provides Update On Its Covid-19 Collaboration With Valneva

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), pertussis, and universal influenza.

Industry

Biotechnology & Drugs

Contact Info

2100 POWELL STREET, SUITE 900

EMERYVILLE, CA

94608

United States

+1.510.8485100

http://www.dynavax.com/

Executive Leadership

Scott D. Myers

Chairman of the Board

David F. Novack

President, Chief Operating Officer

Ryan Spencer

Chief Executive Officer, Director

Kelly MacDonald

Chief Financial Officer, Senior Vice President

John Slebir

Senior Vice President, General Counsel

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.4K
EPS (USD)

2018

-2.550

2019

-2.160

2020

-0.750

2021(E)

0.450
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.79
Price To Book (MRQ)
22.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
325.89
LT Debt To Equity (MRQ)
325.89
Return on Investment (TTM)
-11.37
Return on Equity (TTM)
-6.05

Latest News

Latest News

China's Clover raises $230 million, plans vaccines for COVID-19 variants

China's Clover Biopharmaceuticals, a developer of coronavirus vaccines, has raised $230 million from investors, including Singapore's state investment firm Temasek Holdings, it said on Tuesday, as it develops vaccines for variants.

UPDATE 2-China's Clover ends COVID-19 vaccine partnership with GSK

Clover Biopharmaceuticals has ended its partnership with GlaxoSmithKline Plc to develop a COVID-19 vaccine using its adjuvant, the Chinese drugmaker said on Monday, as it will stick with a vaccine booster from U.S.-based Dynavax instead.

India's Biological E. to start vaccine late-stage trials in April - executive

India's Biological E. Ltd plans to start large late-stage trials of its potential COVID-19 vaccine candidate in April next year, according to a top executive at the Hyderabad-based drugmaker.

China's Clover says its COVID-19 vaccines trigger 'strong immune responses' in early trial

Two coronavirus vaccine candidates developed by China's Clover Biopharmaceuticals triggered strong immune responses in an early-stage human trial and appeared to be safe, the company said on Friday.

China's Clover says its coronavirus vaccine candidate showed promise in animal test

An experimental coronavirus vaccine developed by China's Clover Biopharmaceuticals appeared to be safe and able to trigger immune responses in animal tests, researchers have said.

BRIEF-Dynavax Tech, Times Pharmacy Announce Partnership To Offer Heplisav-B Hepatitis B Vaccine To Customers Throughout Oahu

* DYNAVAX TECHNOLOGIES CORP - CO, TIMES PHARMACY ANNOUNCE PARTNERSHIP TO OFFER HEPLISAV-B HEPATITIS B VACCINE TO CUSTOMERS THROUGHOUT OAHU Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Dynavax Files For Shelf Of Upto 14.6 Million Shares Of Common Stock

* DYNAVAX FILES FOR SHELF OF UPTO 14.6 MILLION SHARES OF COMMON STOCK, INCLUDING SERIES B CONVERTIBLE PREFERRED STOCK, WARRANTS BY SELLING HOLDERS - FILING Further company coverage:

BRIEF-Dynavax Says First Participants Dosed In Trial For Clover's COVID-19 S-Trimer Vaccine Candidate

* DYNAVAX ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL EVALUATING CLOVER BIOPHARMACEUTICALS’ COVID-19 S-TRIMER VACCINE CANDIDATE WITH CPG 1018 ADJUVANT

China's Clover begins human trials of COVID-19 shot with GSK, Dynavax boosters

A potential coronavirus vaccine being developed by China's Clover Biopharmaceuticals using GlaxoSmithKline's vaccine booster is now in early-stage testing in humans, the companies said on Friday.

BRIEF-Dynavax Completes Enrollment Of Trial Evaluating Heplisav-B

* DYNAVAX COMPLETES ENROLLMENT OF CLINICAL TRIAL EVALUATING HEPLISAV-B IN PATIENTS UNDERGOING HEMODIALYSIS

BRIEF-Dynavax Announces Proposed Public Offering Of Common Stock

* DYNAVAX TECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Dynavax Says Intend To Provide Update On Early-Stage Collaborations Regarding Potential Development Of COVID-19 Vaccine

* DYNAVAX TECHNOLOGIES - ON MAY 19, INTENDS TO PROVIDE UPDATE ON EARLY-STAGE COLLABORATIONS REGARDING POTENTIAL DEVELOPMENT OF A VACCINE FOR COVID-19

BRIEF-Dynavax Reports Interim Analysis Of Ongoing Clinical Trial Evaluating Heplisav-B In Patients Undergoing Hemodialysis

* DYNAVAX REPORTS INTERIM ANALYSIS OF ONGOING CLINICAL TRIAL EVALUATING HEPLISAV-B IN PATIENTS UNDERGOING HEMODIALYSIS

BRIEF-Valneva And Dynavax Announce Collaboration To Advance Vaccine Development For Covid-19

* VALNEVA AND DYNAVAX ANNOUNCE COLLABORATION TO ADVANCE VACCINE DEVELOPMENT FOR COVID-19

BRIEF-Dynavax And Sinovac Announce Collaboration To Develop A Coronavirus Vaccine

* DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A CORONAVIRUS (COVID-19) VACCINE

BRIEF-Dynavax And Sinovac Announce Collaboration To Develop A Coronavirus Vaccine

* DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A CORONAVIRUS (COVID-19) VACCINE

BRIEF-Dynavax Donates 10,000 Doses Of Heplisav-B Adult Vaccine

* DYNAVAX TECHNOLOGIES CORP - DONATING 10,000 DOSES OF HEPLISAV-B ADULT VACCINE Source text for Eikon: Further company coverage:

BRIEF-Dynavax And CEPI Announce Collaboration To Support Global Effort To Develop A Vaccine For Coronavirus

* DYNAVAX AND CEPI ANNOUNCE COLLABORATION TO SUPPORT GLOBAL EFFORT TO DEVELOP A VACCINE FOR CORONAVIRUS (COVID-19) Source text for Eikon: Further company coverage:

BRIEF-Dynavax And Cepi Announce Collaboration To Develop Vaccine For Coronavirus

* DYNAVAX AND CEPI ANNOUNCE COLLABORATION TO SUPPORT GLOBAL EFFORT TO DEVELOP A VACCINE FOR CORONAVIRUS (COVID-19)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up